Literature DB >> 30567240

Special form of osteoporosis in a 53-year-old man.

Simon Lampart1, Silvia Azzarello-Burri2, Christoph Henzen1,3, Stefan Fischli3.   

Abstract

Male osteoporosis often remains unrecognised. Osteoporotic fractures occur approximately 10 years later in men than in women due to higher peak bone mass. However, 30% of all hip fractures occur in men. Risk factors of osteoporotic fractures can be grouped into primary and secondary causes. We present the case of a 53-year-old man, who suffered a compression fracture of a lumbar vertebra after a generalised seizure and an atraumatic rib fracture 5 months later. We could exclude secondary causes of bone mineral loss such as primary hyperparathyroidism, glucocorticoid use and hypogonadism. However, a heterozygous missense mutation of the COL1A1 gene in exon 48 in further search of a secondary cause was found. Therapy was changed from bisphosphonate treatment to teriparatide. Considering the lack of other osteogenesis imperfecta (OI) symptoms and signs, the patient's illness can be classified as mild. OI should be considered as differential diagnosis in unexplained cases with osteoporosis. © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  calcium and bone; endocrine system; genetic screening / counselling

Mesh:

Substances:

Year:  2018        PMID: 30567240      PMCID: PMC6301502          DOI: 10.1136/bcr-2018-226672

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  20 in total

Review 1.  Osteogenesis imperfecta: comprehensive management.

Authors:  J C Marini
Journal:  Adv Pediatr       Date:  1988

2.  Mortality after all major types of osteoporotic fracture in men and women: an observational study.

Authors:  J R Center; T V Nguyen; D Schneider; P N Sambrook; J A Eisman
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

3.  The identification of novel mutations in COL1A1, COL1A2, and LEPRE1 genes in Chinese patients with osteogenesis imperfecta.

Authors:  Zhen-Lin Zhang; Hao Zhang; Yao-hua Ke; Hua Yue; Wen-Jin Xiao; Jin-Bo Yu; Jie-Mei Gu; Wei-Wei Hu; Chun Wang; Jin-Wei He; Wen-Zhen Fu
Journal:  J Bone Miner Metab       Date:  2011-06-14       Impact factor: 2.626

Review 4.  Pharmacological and biological therapeutic strategies for osteogenesis imperfecta.

Authors:  Ronit Marom; Yi-Chien Lee; Ingo Grafe; Brendan Lee
Journal:  Am J Med Genet C Semin Med Genet       Date:  2016-11-03       Impact factor: 3.908

Review 5.  Genetic determinants of susceptibility to osteoporosis.

Authors:  Omar M E Albagha; Stuart H Ralston
Journal:  Endocrinol Metab Clin North Am       Date:  2003-03       Impact factor: 4.741

6.  Epidemiology of osteoporosis.

Authors:  C Cooper; L J Melton
Journal:  Trends Endocrinol Metab       Date:  1992-08       Impact factor: 12.015

7.  Hip fractures in the elderly: a world-wide projection.

Authors:  C Cooper; G Campion; L J Melton
Journal:  Osteoporos Int       Date:  1992-11       Impact factor: 4.507

8.  Recurrence of perinatal lethal osteogenesis imperfecta in sibships: parsing the risk between parental mosaicism for dominant mutations and autosomal recessive inheritance.

Authors:  Shawna M Pyott; Melanie G Pepin; Ulrike Schwarze; Kathleen Yang; Gretchen Smith; Peter H Byers
Journal:  Genet Med       Date:  2011-02       Impact factor: 8.822

9.  Evaluation of teriparatide treatment in adults with osteogenesis imperfecta.

Authors:  Eric S Orwoll; Jay Shapiro; Sandra Veith; Ying Wang; Jodi Lapidus; Chaim Vanek; Jan L Reeder; Tony M Keaveny; David C Lee; Mary A Mullins; Sandesh C S Nagamani; Brendan Lee
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

10.  Primary Osteoporosis in Young Adults: Genetic Basis and Identification of Novel Variants in Causal Genes.

Authors:  Corinne Collet; Agnès Ostertag; Manon Ricquebourg; Marine Delecourt; Giulia Tueur; Bertrand Isidor; Pascale Guillot; Elise Schaefer; Rose-Marie Javier; Thomas Funck-Brentano; Philippe Orcel; Jean-Louis Laplanche; Martine Cohen-Solal
Journal:  JBMR Plus       Date:  2017-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.